6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)-quinolinone (cilostazol), a phosphodiesterase type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca2+-activated K+ channels in rabbit hearts

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 1, 2008, Pages 100-104

  Fukasawa, Mika ^a   Nishida, Hirofumi ^a   Sato, Toshiaki ^a   Miyazaki, Masaru ^a   Nakaya, Haruaki ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 BROMO CYCLIC AMP; CALCIUM ACTIVATED POTASSIUM CHANNEL; CILOSTAZOL; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FLAVOPROTEIN; KT 5720; MILRINONE; PAXILLINE; PHOSPHODIESTERASE III INHIBITOR; TRIPHENYLTETRAZOLIUM;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; HEART INFARCTION SIZE; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE WALL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; ISOLATED HEART; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY; SARCOLEMMA; STATISTICAL SIGNIFICANCE;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART; MITOCHONDRIA, HEART; MYOCARDIAL INFARCTION; PHOSPHODIESTERASE INHIBITORS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; RABBITS; TETRAZOLES;

EID: 45749094144     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.136218     Document Type: Article

References (24)

1. Akiyama H, Kudo S, and Shimizu T (1985) The absorption, distribution and excretion of new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Arzneimittelforschung 35:1124-1132.
2. Choi JM, Shin HK, Kim KY, Lee JH, and Hong KW (2002) Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 300:787-793.
3. Gribkoff VK, Lum-Ragan JT, Boissard CG, Post-Munson DJ, Meanwell NA, Starrett JE Jr, Kozlowski ES, Romine JL, Trojnacki JT, Mckay MC, et al. (1996) Effects of channel modulators on cloned large-conductance calcium-activated potassium channels. Mol Pharmacol 50:206-217.
4. Hashimoto A, Miyakoda G, Hirose Y, and Mori T (2006) Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 189:350-357.
5. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
6. Kimura Y, Tani T, Kanabe T, and Watanabe K (1985) Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35:1144-1149.
7. Lochner A, Genade S, Tromp E, Podzuweit T, and Moolman JA (1999) Ischemic preconditioning and the -adrenergic signal transduction pathway. Circulation 100:958-966.
8. Manickavasagam S, Ye Y, Lin Y, Perez-Polo RJ, Huang MH, Lui CY, Hughes MG, McAdoo DJ, Uretsky BF, and Birnbaum Y (2007) The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther 21:321-330.
9. Ca channels. Cardiovasc Res 77:398-405.
10. O'Rourke B (2007) Mitochondrial ion channels. Annu Rev Physiol 69:19-49.
11. Park SY, Lee JH, Kim CD, Lee WS, Park WS, Han J, Kwak YG, Kim KY, and Hong KW (2006) Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-K channel activation. J Pharmacol Exp Ther 317:1238-1245.
12. Remme WJ (1998) The sympathetic nervous system and ischaemic heart disease. Eur Heart J 19:F62-F71.
13. Sanchez M and McManus OB (1996) Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel. Neuropharmacology 35:963-968.
14. + channels in cardiac myocytes: a mechanism of the cardioprotective effect and modulation by protein kinase A. Circulation 111:198-203.
15. Ca channel in smooth muscle. Trends Pharmacol Sci 22:505-512.
16. Shakur Y, Fong M, Hensley J, Cone J, Movsesian MA, Kambayashi J, Yoshitake M, and Liu Y (2002) Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc Drugs Ther 16:417-427.
17. + channel opening requires superoxide radical generation. Am J Physiol Heart Circ Physiol 290:H434-H440.
18. ATP channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest 109:509-516.
19. Tanaka K, Gotoh F, Fukuuchi Y, Amano T, Uematsu D, Kawamura J, Yamayaki T, Itoh N, Obara K, and Muramatsu K (1989) Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 20:668-673.
20. Tong H, Bernstein D, Murphy E, and Steenbergen C (2005) The role of β-adrenergic receptor signaling in cardioprotection. FASEB J 19:983-985.
21. Wakida K, Morimoto N, Shimazawa M, Hozumi I, Nagase H, Inuzuka T, and Hara H (2006) Cilostazol reduces ischemic brain damage partly by inducing metallothionein-1 and -2. Brain Res 1116:187-193.
22. 3 cells and pheochromocytoma PC12 cells. Endocrinology 145:1175-1184.
23. + channels in the cardiac inner mitochondrial membrane. Science 298:1029- 1033.
24. Ye YL, Shi WZ, Zhang WP, Wang ML, Zhou Y, Fang SH, Liu LY, Zhang Q, Yu YP, and Wei EQ (2007) Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries. Eur J Pharmacol 557:23-31.